Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities:
Net loss	$ (63,223)	$ (11,959)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	304	900
Loss (gain) on disposal of equipment	(44)	8
Noncash interest expense	22	50
Share-based compensation	1,856	430
Writeoff of in process R&D	50,618	0
Change in fair value of derivative liability	0	556
ROU asset amortization	518	0
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(200)	(982)
Other long-term assets	0	32
Accounts payable	(502)	952
Accrued expenses	(398)	(1,998)
Operating lease liability	(495)	0
Settlement of derivative liability	0	(1,050)
Net cash used in operating activities	(11,544)	(13,061)
Cash flows from investing activities:
Purchases of property and equipment	(424)	(16)
Asset acquistion costs	(318)	0
Proceeds from sale of equipment	115	55
Net cash (used in) provided by investing activities	(627)	39
Cash flows from financing activities:
Proceeds from issuance of common stock	0	60,482
Issuance costs from issuance of common stock	0	(5,517)
Repayment of borrowings under loan	(3,750)	(1,875)
Net cash (used in) provided by financing activities	(3,750)	53,090
Net change in cash, cash equivalents and restricted cash	(15,921)	40,068
Cash, cash equivalents and restricted cash at beginning of period	47,339	25,566
Cash, cash equivalents and restricted cash at end of period	31,418	65,634
Supplemental disclosure of cash flow information
Cash paid for interest	226	486
Supplemental disclosure of financing activities
Acquisition of equipment included in accrued expenses	0	0
Deferred offering costs included in accrued expenses	0	(1,384)
Payment to non-participating Compass LLC investors, within accrued expenses	0	(69)
ROU asset acquired through operating leases	5,148	0
Acquisition of Trigr Therapeutics, Inc.	$ 50,300	$ 0